Berning, Philipp http://orcid.org/0000-0002-4152-0366
Schmitz, Norbert http://orcid.org/0000-0003-4938-7528
Ngoya, Maud
Finel, Hervé
Boumendil, Ariane
Wang, Fengrong
Huang, Xiao-Jun
Hermine, Olivier
Philippe, Laure
Couronné, Lucile
Jaccard, Arnaud http://orcid.org/0000-0001-7091-8253
Liu, Daihong http://orcid.org/0000-0003-3334-9113
Wu, Depei
Reinhardt, Hans Christian
Chalandon, Yves http://orcid.org/0000-0001-9341-8104
Wagner-Drouet, Eva http://orcid.org/0000-0002-0728-2253
Kwon, Mi
Zhang, Xi http://orcid.org/0000-0002-8548-2832
Carpenter, Ben
Yakoub-Agha, Ibrahim http://orcid.org/0000-0003-4524-8782
Wulf, Gerald
López-Jiménez, Javier
Sanz, Jaime
Labussière-Wallet, Hélène
Shimoni, Avichai
Dreger, Peter http://orcid.org/0000-0002-7429-8570
Sureda, Anna
Kim, Won Seog
Glass, Bertram
Article History
Received: 13 March 2023
Revised: 22 April 2023
Accepted: 27 April 2023
First Online: 8 May 2023
Competing interests
: HCR received consulting and lecture fees from Abbvie, AstraZeneca, BMS, Roche, Vertex, and Merck. HCR received research funding from Gilead Pharmaceuticals and AstraZeneca. HCR is a co-founder of CDL Therapeutics GmbH. YC received consulting fees from MSD, Novartis, Incyte, BMS, Pfizer, Abbvie, Roche, Jazz, Gilead, Amgen, Astra-Zeneca, Servier; Travel support from MSD, Roche, Gilead, Amgen, Incyte, Abbvie, Janssen, Astra-Zeneca, Jazz. AS received research grants from Takeda, BMS/Celgene. AS received consulting fees from Takeda, BMS/Celgene, Novartis, Janssen, Gilead, and Sanofi. AS received honoraria from Takeda, BMS/Celgene, MSD, Janssen, Amgen, Novartis, Gilead Kite, Sanofi, Roche, and Alexion. The remaining authors declare no competing financial interests.